Horizon Discovery Signs Distribution Agreement with Haplogen
News Feb 13, 2014
Horizon Discovery™ (Horizon) has announced that it has signed a worldwide distribution agreement with Haplogen GmbH (Haplogen), with immediate effect. Under the terms of the agreement customers can now access, directly from Horizon, Haplogen’s Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes.
This agreement represents the first time that Horizon will be distributing another company’s products, recognizing Horizon’s past success in penetrating the global model cell lines market.
Haploid cellular models offer a biologically relevant system for in vitro genetic analyses of molecular, cellular, and developmental events in various cell lineages. Haplogen’s Haploid Gene Trap Mutant Collection is the largest haploid cell line bank available, and comprises over 9,400 mutant clones, affecting over 3,700 human genes and an additional 1,600 inducible clones covering 1,100 genes.
For-profit customers will be able to access the cell-line bank by signing an annual limited use label license, whilst academic customers will be able to access an unlimited term license and will receive a greater than 90% discount.
“Horizon’s mission is to give scientists access to high value products and services that address their research needs,” commented Dr Darrin Disley, CEO, Horizon. “The addition of the Haplogen cell line products to our offering supports our growth strategy and is highly complementary to our current product portfolio, including our X-MAN™ range of diploid isogenic cell lines. We anticipate announcing further partnerships in the future as we continue to broaden our product offering to meet the needs of our customers.”
Dr Georg Casari, CEO, Haplogen, said: “We are delighted that a company of Horizon’s reputation and commercial reach is recognizing the potential of our Haploid Gene Trap Mutant Collection. This marketing and distribution agreement will help make our products accessible to a much broader range of customers active in the translational genomics field.”
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Study Indicates 75% of Human Genome is Non-functionalNews
An evolutionary biologist at the University of Houston has published new calculations that indicate no more than 25 percent of the human genome is functional.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Course: Next Generation Sequencing: RNA Sequencing Library Preparation
Apr 23 - Apr 27, 2018
EMBO Practical Course: Microbial Metagenomics: A 360º Approach
Apr 23 - Apr 30, 2018
EMBL Course: Next Generation Sequencing: Whole Genome Sequencing Library Preparation
Apr 16 - Apr 20, 2018
EMBL Course: Introduction to Next Generation Sequencing
Apr 09 - Apr 12, 2018